MARKET

GNCA

GNCA

Genocea
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.240
+0.190
+9.27%
Closed 16:00 11/14 EST
OPEN
2.010
PREV CLOSE
2.050
HIGH
2.310
LOW
2.010
VOLUME
138.55K
TURNOVER
--
52 WEEK HIGH
11.28
52 WEEK LOW
1.990
MARKET CAP
70.28M
P/E (TTM)
-1.1803
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of GNCA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

GNCA News

  • Genocea to Present at the Stifel 2019 Healthcare Conference
  • GlobeNewswire.13h ago
  • Genocea Biosciences Enters Oversold Territory
  • Zacks.22h ago
  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.22h ago
  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.1d ago

More

Industry

Biotechnology & Medical Research
-0.05%
Pharmaceuticals & Medical Research
-0.27%

Hot Stocks

Name
Price
%Change

About GNCA

Genocea Biosciences, Inc. is a biopharmaceutical company developing personalized cancer immunotherapies. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, the Company can improve neoantigens for inclusion in its immunotherapies and exclude inhibitory antigens that exert an immunosuppressive effect on anti-tumor immune responses. It provides GEN-009 program, which is a neoantigen vaccine candidate. The Company is conducting a Phase 1/2a clinical trial across a range of solid tumor types. It also provides GEN-011, which is a neoantigen-specific adoptive T cell therapy.
More

Webull offers Genocea Biosciences Inc (GNCA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.